10 Recruiting Carcinoma, Non-Small-Cell Lung Phase 1 / Phase 2 Clinical Trials
Active phase 1 / phase 2 studies for carcinoma, non-small-cell lung enrolling across the USA. Verify eligibility and contact site coordinators.
All Carcinoma, Non-Small-Cell Lung studiesPhase 1 / Phase 2 Studies for Carcinoma, Non-Small-Cell Lung
Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination Study
π Research Site β La Jolla, California
View Study & Checklist βStudy of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
π University of Alabama at Birmingham β Birmingham, Alabama
View Study & Checklist βA Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer
π University of Alabama at Birmingham, Comprehensive Cancer Center β Birmingham, Alabama
View Study & Checklist βA Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung Cancer
π City of Hope β Duarte, California
View Study & Checklist βA Study of TAK-788 in Adults With Non-Small Cell Lung Cancer
π Brookwood Medical Center β Birmingham, Alabama
View Study & Checklist βA Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer
π Research Site β Atlanta, Georgia
View Study & Checklist βMK-3475 and Gemcitabine in Non-Small Cell Lung Cancer (NSCLC)
π Providence Oncology & Hematology Care Clinic - Eastside β Portland, Oregon
View Study & Checklist βKEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naΓ―ve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)
π Banner MD Anderson Cancer Center ( Site 0001) β Gilbert, Arizona
View Study & Checklist βA Study of DM005 in Patients With Advanced Solid Tumors
π Henry Ford Cancer Institute β Detroit, Michigan
View Study & Checklist βA Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer
π New York University Langone Medical Center β New York, New York
View Study & Checklist β